Which approach offers safer biliary drainage?

See the #UEGWeek findings from “Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT” 🔎

Hear from #UEGWeek top abstract awardee Nurulamin Noor as he discusses the PROFILE findings showing less need for surgery and less disease progression with early top-down anti-TNF therapy versus conventional step-up treatment in Crohn’s disease.

▶️ Watch the full interview.

Fewer flares, less need for glucocorticoid rescue therapy.

At #UEGWeek, the Phase 3 INDIGO trial found that obexelimab reduced flare risk by 56% compared with placebo in adults with IgG4-related disease, with more patients achieving complete remission.

Take a closer look 🔍

Could a shorter antibiotic course be enough for acute cholangitis? 🎤

Hear from #UEGWeek top abstract awardee Anouk Overdevest about the COBRA trial comparing 1 day with 4–7 days of antibiotics after adequate biliary drainage.

Watch her interview to learn more.

🔬 Early treatment, lasting benefits. Presented at #UEGWeek, five-year follow-up of the PROFILE trial showed improved long-term outcomes with early top-down anti-TNF therapy versus conventional step-up treatment in newly diagnosed Crohn’s disease.

See the findings at a glance!

Ductular reaction is a feature of advanced MASLD, but its role in disease progression remains unclear.

💡 Hear #UEGWeek top abstract awardee Dania El Abyad discuss research exploring how it interacts with the immune microenvironment and relates to clinical outcomes.

Presented today at #UEGWeek, the PEPPER trial compared three deprescribing strategies with similar success rates. At 1 year, 43.2% of participants were taking fewer than 4 PPI doses per month and were willing to continue this approach.

🔍 Explore our infographic!

A meaningful advance for patients with IgG4-related disease.

Hear from top abstract awardee Emma Culver at #UEGWeek on how obexelimab reduced flares and the need for glucocorticoid rescue therapy in the Phase 3 INDIGO trial 🎥

💧 A more efficient approach to colorectal ESD? A trial presented yesterday at #UEGWeek found underwater ESD was non-inferior to conventional ESD for en bloc resection, with shorter procedure times and less intraprocedural bleeding.

View our visual recap.

💊 Unveiled at #UEGWeek, new research links antibiotic use from childhood through early adulthood to higher odds of IBS at age 24, with the odds increasing as prescriptions rose.

Read the full press release for the findings: https://bit.ly/4zG0csC

📣 Late-Breaking news!

Hear from #UEGWeek presenter Bas Groot Koerkamp as he discusses the study: Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT ▶️

Immune changes could signal IBD up to 10 years before diagnosis.

New research at #UEGWeek identified distinct antibody patterns before Crohn’s disease and ulcerative colitis diagnosis, suggesting potential for earlier risk detection.

🔍 Read more: https://bit.ly/4zKyTNU

🔬 What role does ductular reaction play in MASLD? Research presented yesterday at #UEGWeek suggests its pro-inflammatory form may actively shape the liver’s immune microenvironment.

Read our bitesize recap.

Rightly one of the best abstracts @myueg.bsky.social

My latest #selfiewiththepresident @myueg.bsky.social #UEGWEEK @joostphdrenth.bsky.social

Less time, less intraprocedural bleeding and the same en bloc resection rate – new trial findings at #UEGWeek comparing underwater with conventional colorectal ESD.

🔍 Watch top abstract awardee Arianna Andreozzi unpack today’s results.

📊 A shorter course, similar cure rates: presented today at #UEGWeek, the COBRA trial found that 1 day of antibiotics was non-inferior to 4–7 days for acute cholangitis after adequate biliary drainage.

Explore the key findings in our infographic!

🌍 A growing burden across borders. New research at #UEGWeek projects sharply rising disability associated with alcohol-related cirrhosis complicated by heart failure across Central and Eastern Europe and the US by 2050.

Explore the findings: https://bit.ly/4dFSK8f

🔍 Vague symptoms predict poorer outcomes in #PancreaticCancer

🔸StageIV disease was more frequent (62% vs 40%)
🔸Fewer received tumour-reductive treatment (34% vs 50%)
🔸Mortality risk remained 48% higher after adjustment

Read more in UEG Journal:
👉 https://bit.ly/4A4aXWI

🛡️ Immunogenicity does not compromise outcomes with subcutaneous #infliximab

🔸Anti-drug antibodies (#ADAs) lowered drug levels but not 1-year efficacy or safety
🔸Treatment persistence remained similar regardless of ADA status

Find out more in this UEG Journal article:
👉 https://bit.ly/3UESgZp